US74349U1088 - Common Stock
PROMETHEUS BIOSCIENCES INC
NASDAQ:RXDX (6/15/2023, 7:23:19 PM)
After market: 199.95 +0.03 (+0.02%)199.92
+0.18 (+0.09%)
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
PROMETHEUS BIOSCIENCES INC
3050 Science Park Road, #342
San Diego CALIFORNIA 92121
P: 18584224300.0
CEO: Mark C. McKenna
Employees: 97
Merck & Co.’s Keytruda and Gardasil soundly beat analysts’ estimates for quarterly sales, driving the company’s annual revenue forecast higher even as costs for its acquisition of Prometheus Biosciences Inc. led to a cut in its annual earnings outlook.
The company may be riding the wave of an AI healthcare boom.
The company has several promising autoimmune therapies.
The drugmaker is still a work in progress.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on RXDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: